CD93 and glioma: Our analysis results revealed notably higher levels of CD93 expression among IDH wild forms, non-codeleted 1p19q subforms, and unmethylated MGMT promoter subforms in comparison to levels in gliomas of the IDH mutation subtype (Fig. 1c, d for total WHO grades; e, f for low WHO grade; g, h for high WHO grades) and the codeleted 1p19q subform (Fig. 1i, j) in combination with methylated MGMT promoter subtype (Fig. 1k, l) according to the TCGA and CGGA databases.